Effects of peripheral vasculopathy, such as Raynaud’s phenomenon, have been observed in postmarketing reviews and at the therapeutic dosages of CNS stimulants in all age teams all through the program of remedy. Signs and indicators commonly enhanced soon after dosage reduction or discontinuati